Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
Boehringer Ingelheim
Medtronic
McKinsey
Johnson and Johnson

Last Updated: January 19, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MUPIROCIN

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

All Clinical Trials for Mupirocin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00108160 Preventing Staphylococcal (Staph) Infection Completed Saint Joseph Mercy Health System Phase 4 2005-04-01 The purpose of this study is to determine if mupirocin 2% in polyethylene glycol (PEG) ointment [Treatment Arm] is effective in preventing moderate to severe re-infection with Staphylococcus aureus compared with treatment with polyethylene glycol (PEG) ointment [Placebo Arm].
NCT00108160 Preventing Staphylococcal (Staph) Infection Completed University of Michigan Phase 4 2005-04-01 The purpose of this study is to determine if mupirocin 2% in polyethylene glycol (PEG) ointment [Treatment Arm] is effective in preventing moderate to severe re-infection with Staphylococcus aureus compared with treatment with polyethylene glycol (PEG) ointment [Placebo Arm].
NCT00108160 Preventing Staphylococcal (Staph) Infection Completed VA Office of Research and Development Phase 4 2005-04-01 The purpose of this study is to determine if mupirocin 2% in polyethylene glycol (PEG) ointment [Treatment Arm] is effective in preventing moderate to severe re-infection with Staphylococcus aureus compared with treatment with polyethylene glycol (PEG) ointment [Placebo Arm].
NCT00156377 Prophylaxis With Intranasal Mupirocin for Prevention of S. Aureus Infections Completed GlaxoSmithKline Phase 4 2002-11-01 In order to evaluate the effect of eliminating nasal carriage by mupirocin prophylaxis on subsequent Staphylococcus aureus infection, a prospective randomized trial was performed particularly including patients with predisposing risk factors for S. aureus infections.
NCT00156377 Prophylaxis With Intranasal Mupirocin for Prevention of S. Aureus Infections Completed University Hospital Muenster Phase 4 2002-11-01 In order to evaluate the effect of eliminating nasal carriage by mupirocin prophylaxis on subsequent Staphylococcus aureus infection, a prospective randomized trial was performed particularly including patients with predisposing risk factors for S. aureus infections.
NCT00179959 The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis Completed Johnson & Johnson Phase 4 2005-09-01 Staphylococcus aureus (S. aureus) infection is perceived not only as a common secondary complication of atopic dermatitis (AD), but also as a culprit in the worsening of this condition. In addition, the recent development of community acquired methicillin-resistant S. aureus (CA-MRSA) has presented a new challenge to our management of AD, both in treatment of acute infections and maintenance therapy. The investigators would like to perform a randomized investigator-blinded placebo-controlled study of children aged 6 months to 17 years with moderate to severe atopic dermatitis with clinical signs of secondary bacterial infection to study: 1) the prevalence of CA-MRSA in our patient population; 2) the relationship of sensitivity of the S. aureus organism cultured from the infected lesion(s) to clinical response to oral cephalexin therapy and severity of the AD; and 3) whether concurrent treatment of S. aureus infection initially with nasal mupirocin ointment and sodium hypochlorite (bleach) baths can result in long-term S. aureus eradication and clinical stability.
NCT00179959 The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis Completed Society for Pediatric Dermatology Phase 4 2005-09-01 Staphylococcus aureus (S. aureus) infection is perceived not only as a common secondary complication of atopic dermatitis (AD), but also as a culprit in the worsening of this condition. In addition, the recent development of community acquired methicillin-resistant S. aureus (CA-MRSA) has presented a new challenge to our management of AD, both in treatment of acute infections and maintenance therapy. The investigators would like to perform a randomized investigator-blinded placebo-controlled study of children aged 6 months to 17 years with moderate to severe atopic dermatitis with clinical signs of secondary bacterial infection to study: 1) the prevalence of CA-MRSA in our patient population; 2) the relationship of sensitivity of the S. aureus organism cultured from the infected lesion(s) to clinical response to oral cephalexin therapy and severity of the AD; and 3) whether concurrent treatment of S. aureus infection initially with nasal mupirocin ointment and sodium hypochlorite (bleach) baths can result in long-term S. aureus eradication and clinical stability.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Mupirocin

Condition Name

Condition Name for Mupirocin
Intervention Trials
Staphylococcus Aureus 8
Methicillin-resistant Staphylococcus Aureus 5
Surgical Site Infection 4
Impetigo 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Mupirocin
Intervention Trials
Infection 23
Staphylococcal Infections 19
Communicable Diseases 16
Surgical Wound Infection 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Mupirocin

Trials by Country

Trials by Country for Mupirocin
Location Trials
United States 125
Ukraine 8
South Africa 6
Argentina 6
Netherlands 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Mupirocin
Location Trials
Missouri 10
Texas 8
Florida 7
New York 7
Tennessee 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Mupirocin

Clinical Trial Phase

Clinical Trial Phase for Mupirocin
Clinical Trial Phase Trials
Phase 4 27
Phase 3 9
Phase 2/Phase 3 2
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Mupirocin
Clinical Trial Phase Trials
Completed 30
Recruiting 17
Not yet recruiting 7
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Mupirocin

Sponsor Name

Sponsor Name for Mupirocin
Sponsor Trials
GlaxoSmithKline 7
University of California, Irvine 4
Washington University School of Medicine 4
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Mupirocin
Sponsor Trials
Other 98
Industry 19
U.S. Fed 9
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Baxter
Mallinckrodt
Express Scripts
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.